High-Risk Neuroblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Neuroblastoma stands as the most prevalent cancer in children below the age of one and constitutes the primary solid tumor found outside the central nervous system across all age brackets. Its clinical behavior encompasses a wide range, delineated into three risk groups: low, medium, and high. Approximately 50% of neuroblastoma cases fall into the high-risk category, determined by age, disease extent, histological findings, and cytogenetic characteristics such as MYCN amplification and DNA ploidy. Notably, children over 18 months with metastatic disease are classified as high-risk due to historically poor outcomes in this subgroup. MYCN amplification also places patients in the high-risk category, except those with L1 MYCN amplified disease undergoing complete resection. The management of high-risk neuroblastoma poses significant challenges and necessitates a comprehensive approach involving multiple modalities. The treatment protocol encompasses chemotherapy, surgical resection, high-dose chemotherapy with autologous stem cell rescue, radiation therapy, immunotherapy, and isotretinoin. The duration of the current treatment regimen spans approximately 18 months. In a significant development, as of December 2023, the Food and Drug Administration has approved eflornithine (IWILFIN, USWM, LLC) to mitigate the risk of relapse in both adult and pediatric patients grappling with high-risk neuroblastoma (HRNB).

Thelansis’s “High-Risk Neuroblastoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential High-Risk Neuroblastoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of High-Risk Neuroblastoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

High-Risk Neuroblastoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: High-Risk Neuroblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033